CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
CytoDyn Inc. (OTCQB: CYDY) will hold a webcast on December 29, 2022, at 8:00 a.m. PT to discuss the performance of its investigational drug, leronlimab, in clinical trials.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CytoDyn Inc. (OTCQB: CYDY) will hold a webcast on December 29, 2022, at 8:00 a.m. PT to discuss the performance of its investigational drug, leronlimab, in clinical trials. The discussion will also address recent charges against former CEO Nader Pourhassan, who was terminated on January 24, 2022, and has since had no association with the company. CytoDyn is focused on developing leronlimab for various therapeutic applications, including infectious diseases, cancer, and autoimmune conditions. The webcast replay will be available until January 29, 2023.
Positive
- Webcast scheduled to discuss leronlimab's clinical trial performance.
- Focus on multiple therapeutic indications for leronlimab.
Negative
- Recent charges against former CEO Nader Pourhassan could raise concerns about management stability.
Details
News Market Reaction – CYDY
The recorded move for CYDY in the trading session of this news was +3.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.
Webcast Access Information
| Date: | Thursday, December 29, 2022 |
| Time: | 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time |
| Access: | https://event.choruscall.com/mediaframe/webcast.html?webcastid=i2RX9JZG |
The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until January 29, 2023.
About CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions.
CONTACTS
Investors:
Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com
Media:
Greg Salsburg
STiR Communications
info@stir-communications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.